ALAWAY Drug Patent Profile
✉ Email this page to a colleague
When do Alaway patents expire, and what generic alternatives are available?
Alaway is a drug marketed by Bausch And Lomb and Bausch And Lomb Inc and is included in two NDAs.
The generic ingredient in ALAWAY is ketotifen fumarate. There are five drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ketotifen fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alaway
A generic version of ALAWAY was approved as ketotifen fumarate by APOTEX INC on May 9th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALAWAY?
- What are the global sales for ALAWAY?
- What is Average Wholesale Price for ALAWAY?
Summary for ALAWAY
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 13 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Patent Applications: | 1,095 |
| What excipients (inactive ingredients) are in ALAWAY? | ALAWAY excipients list |
| DailyMed Link: | ALAWAY at DailyMed |
Pharmacology for ALAWAY
| Drug Class | Histamine-1 Receptor Inhibitor |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for ALAWAY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | ALAWAY | ketotifen fumarate | SOLUTION/DROPS;OPHTHALMIC | 021996-001 | Dec 1, 2006 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb Inc | ALAWAY | ketotifen fumarate | SOLUTION/DROPS;OPHTHALMIC | 208158-001 | Sep 24, 2020 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
